Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state
Publication date: November 2026 Source: Drug Metabolism and Disposition, Volume 54, Issue 11 Author(s): Alexander David James, Frederic Lozac’h, Melissa Hackling, Marie-Anne Lozac’h, Bharti Shah, Jeanne Hardy, Anton Drollmann, Ad Roffel, Gilbert Lefèvre
Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state. // Drug Metabolism and Disposition. – URL: https://www.sciencedirect.com/science/article/pii/S0090955626006860?dgcid=rss_sd_all
Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state. Drug Metabolism and Disposition. https://www.sciencedirect.com/science/article/pii/S0090955626006860?dgcid=rss_sd_all
“Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state.” Drug Metabolism and Disposition.
@article{article43595,
title = {Absorption, distribution, metabolism, excretion, and pharmacokinetics of remibrutinib, an oral, highly selective Bruton tyrosine kinase inhibitor, in healthy participants at steady state},
journal = {Drug Metabolism and Disposition},
url = {https://www.sciencedirect.com/science/article/pii/S0090955626006860?dgcid=rss_sd_all}
}
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01953-z IRAK4 inhibitor DW18134 ameliorates diffuse large B-cell lymphoma in combination with ibrutinib and overcomes acquired resistance to ibrutinib
Acta Pharmacologica Sinica, Published online: 16 November 2026; doi:10.1038/s41401-026-01958-8 Artificial intelligence aids multi-omics data integration in cancer drug discovery and development: from targets to drug synergy
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00179-2 The NIH’s P. J. Brooks discusses the challenges and opportunities ahead for gene therapies and gene editing for diseases of no commercial interest.
Nature Reviews Drug Discovery, Published online: 13 November 2026; doi:10.1038/d41573-026-00181-8 Merck and Moderna’s intismeran autogene succeeded in a landmark melanoma trial, but the oncology community still has more questions than...